Tapan Mehta, MD
Cardiovascular Disease · Boston, MANPI 1962840744
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (58.5%), food and beverage and education — rather than concentrated in one kind of arrangement. Balt USA, LLC accounts for 70.0% of it on its own, with 5 other manufacturers making up the rest. 2025 is the largest year on record at $830, 2.6 times the $314 reported in 2019.
Across 15 payments — averaging $193.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Balt USA, LLC$2K
- Abiomed$511
- Astellas Pharma US Inc$198
- Boston Scientific$95
- Abbott$48
- Amgen$21
What the payments were for
- Travel & lodging$1,70259%
- Food & beverage$1,00735%
- Education$1987%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Balt USA, LLC | 6 | $2,034 |
| Abiomed | 4 | $511 |
| Astellas Pharma US Inc | 2 | $198 |
| Boston Scientific | 1 | $95 |
| Abbott | 1 | $48 |
| Amgen | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Optima Coil System$2,093
- Eclipse 2L$552
- Prestige Coil System$464
- Carrier Delivery Catheter$464
- Impella$322
How this compares
$2,907 in reported general payments places this provider in the 60th percentile of 750 cardiovascular disease providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 145 | $233,440 |
| EntrestoSacubitril/Valsartan | 136 | $199,843 |
| EliquisApixaban | 24 | $39,300 |
| FarxigaDapagliflozin Propanediol | 33 | $36,059 |
| Torsemide | 103 | $4,358 |
| Metoprolol Succinate | 273 | $3,808 |
| Bumetanide | 31 | $3,340 |
| Rosuvastatin Calcium | 36 | $1,466 |
| Potassium Chloride | 35 | $1,329 |
| Spironolactone | 161 | $1,167 |
| Eplerenone | 12 | $848 |
| Ezetimibe | 27 | $777 |
| Atorvastatin Calcium | 104 | $765 |
| Valsartan | 23 | $732 |
| Carvedilol | 74 | $635 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Boston
- Marc SabatineBoston$3.9M
- Elizabeth NabelBoston$2.2M
- Kenneth RosenfieldBoston$1.4M
- James JanuzziBoston$1.1M
- Muthiah VaduganathanBoston$972K
- Joseph LoscalzoBoston$926K
- Sunil KapurBoston$823K
- Paul ZeiBoston$786K
- Paul RidkerBoston$572K
- Ignacio Inglessis-AzuajeBoston$545K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.